Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 8/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.45 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20087747 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3BACE1MAPT | |
| SCHEMBL2951287 | 0.83 | NPC1 (0.53) | MAPT | |
| SCHEMBL14461607 | 0.71 | CYP3A4 (0.42) | SLC6A3BACE1MAPTCYP3A4CYP2C9 | |
| SCHEMBL7306558 | 0.71 | CYP3A4 (0.45) | SLC6A2SLC6A4SLC6A3BACE1MAPT | |
| SCHEMBL27611903 | 0.70 | BACE1 (0.58) | BACE1CYP3A4CYP2C9CYP2C19ANPEP | |
| SCHEMBL20088011 | 0.70 | BACE1 (0.58) | BACE1CYP3A4CYP2C9CYP2C19ANPEP | |
| SCHEMBL26326658 | 0.70 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3MAPTGABBR2 | |
| SCHEMBL5360150 | 0.69 | BACE1 (0.62) | BACE1CYP3A4CYP2C9CYP2C19ANPEP | |
| Ammonia Solution, Strong SCHEMBL7243545 | 0.67 | CYP3A4 (0.49) | BACE1CYP3A4CYP2C9CYP2C19ANPEP | |
| SCHEMBL22288286 | 0.67 | MAOA (0.53) | SLC6A2SLC6A4SLC6A3MAPTGABBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4252848-A2 | OXYSTEROLS AND METHODS OF USE THEREOF | Sage Therapeutics, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3529257-B1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20210380631-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2021-12-09 | — | — | US | disclosed |
| US-11149054-B2 | Oxysterols and methods of use thereof | SAGE THERAPEUTICS, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20190248829-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2019-08-15 | — | — | US | disclosed |
| WO-2018075699-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380631-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | NR1H3, NR1H2, HSD17B7 | SLC6A2 1463/4885SLC6A4 1718/4885SLC6A3 1881/4885 |
| US-20190248829-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | NR1H3, NR1H2, HSD17B7 | SLC6A2 1384/4885SLC6A4 1639/4885SLC6A3 1827/4885 |
| US-11149054-B2 | Oxysterols and methods of use thereof | NR1H3, NR1H2, HSD17B7 | SLC6A2 1384/4885SLC6A4 1639/4885SLC6A3 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.